Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 20, 2026American Journal of Respiratory and Critical Care Medicine

A41-05 From Treatment to Trauma: A Case of Mirvetuximab-Soravtansine Induced Interstitial Lung Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

DVD ValivetiCGC GansonJGJ Garza

Discussion

Loading...

Member takes

Overview

Case report reveals life-threatening interstitial lung disease in a patient treated with Mirvetuximab, suggesting vigilance for drug toxicity.

Key Points

  • To report a case of life-threatening interstitial lung disease induced by Mirvetuximab treatment in a patient with metastatic uterine cancer.
  • Case report of an 80-year-old female with metastatic uterine cancer on Mirvetuximab presenting with hypoxia and lung infiltrates.
  • Evaluation through chest imaging and bronchoalveolar lavage for diagnosis of drug-induced ILD.
  • Patient received broad-spectrum antibiotics and intravenous steroids following diagnosis.
  • Patient exhibited progressive dyspnea and bilateral lung infiltrates suggestive of organizing pneumonia.
  • Bronchoalveolar lavage showed lymphocyte predominance and increased CD8+ count.
  • Condition deteriorated, leading to hospice care after failure to improve.

Cite This Study

Valiveti et al. (2026) studied this question.

synapsesocial.com/papers/6a0d5098f03e14405aa9c7achttps://doi.org/10.1093/ajrccm/aamag162.2913
View Full Paper
Ask AI
Bookmark
Share